



The Rules on formation of marginal prices and markups for medicines are amended

Contacts

Timur Zhursunov
Partner
Tax and Legal Services
timur.zhursunov@pwc.com

Yerkebulan Rakhmenov
Director
Legal Services
yerkebulan.rakhmenov@pwc.com

Alima Syrayeva
Manager
Legal Services
alima.syrayeva@pwc.com

Zhanar Alikulova
Manager
Legal Services
zhanar.alikulova@pwc.com

If you are interested in additional information, please contact us.

Briefly

The Minister of Healthcare adopted the Order dated 3 July 2023 No.124, amending the Rules on regulation, formation of marginal prices and markups for medicines, and medical devices within the framework of the guaranteed volume of free medical care (“GVFMC”) and (or) the obligatory social medical insurance (“OSMI”).

In details

The amendments to the Rules envisage the following:

- The over-the-counter medicines for wholesale and retail realisation are excluded from the pricing regulation.
- The medicines, for which the registration certificates are obtained within the EAEU, could be included into the draft list of medicines, subject to pricing regulation for wholesale and retail realisation.
- The changes are introduced to the list of documents for local and foreign manufacturers of medicines, which should be filed together with the application for registration of marginal prices (1) within GVFMC and OSMI; and (2) for wholesale and retail realisation.

The amendments to the Rules came into force on 16 July 2023.

Are you interested in this topic?

- We would be pleased to discuss with you the above amendments and how they can impact your business.
- We can analyze and implement possible steps to ensure compliance with the new requirements.

If you are interested in additional information, please contact PwC specialists working as part of a group serving your company, or to any of the persons listed.